

CURRICULUM VITAE

Laura C. Chambers, PhD, MPH

Contact Information

Department of Epidemiology
Brown University School of Public Health
121 South Main Street
Providence, Rhode Island 02903
E-mail: laura_chambers@brown.edu

Education

University of Michigan, Ann Arbor, MI. Non-Degree Seeking, Field Research Courses	2006
George Washington University, Washington, DC. BS, Public Health & Honors Program Advisor: Richard Skolnik, MPA	2006-2010
University of Washington, Seattle, WA. MPH, Epidemiology Advisor: Julia Dombrowski, MD, MPH	2014-2016
University of Washington, Seattle, WA. PhD, Epidemiology Advisor: Lisa Manhart, PhD, MPH	2016-2019

Professional Positions

Laboratory Researcher (summers), Molecular Imaging Program, Stanford University	2007-2008
Laboratory Researcher, Department of Pharmacology & Physiology, George Washington University	2008-2009
Senior Fellow (summer), Humanity in Action, France	2009
Principal Research Assistant, Richard Skolnik's textbook <i>Global Health 101</i>	2010
Peace Corps Volunteer, Community Health Program, Peru	2010-2012
Bilingual Research Analyst II, Institute for Medicine & Public Health, Vanderbilt University	2012-2014
Research Study Manager, Department of Epidemiology, University of Washington	2014-2019
Research Scientist, Department of Epidemiology, University of Washington	2019-2020
Lead of Risk & Protective Factors Epidemiology Team / Inter-Agency Projects, Substance Use Epidemiology Program, Rhode Island Department of Health	2019-2020
Deputy Lead, COVID-19 Data & Analytics, Rhode Island Department of Health	2020-2021
Adjunct Assistant Professor, Department of Epidemiology, Brown University School of Public Health	2020-2022
Lead, COVID-19 Data & Analytics, Rhode Island Department of Health	2021
Postdoctoral Research Fellow, Division of Infectious Diseases, The Miriam Hospital, & Department of Medicine, Brown University	2021-2022
Consultant Epidemiologist, Substance Use Epidemiology & COVID-19 Data & Analytics Programs, Rhode Island Department of Health	2021-2022
Lead Research Scientist, People, Place, and Health Collective, Brown University School of Public Health	2022-current
Assistant Professor of the Practice of Epidemiology, Department of Epidemiology, Brown University School of Public Health	2022-current

Honors, Awards, & Scholarships

Presidential Academic Scholarship, George Washington University	2006-2010
Undergraduate Research Award, George Washington University	2008-2009
Goldwater Scholarship & Excellence in Education Award: Honorable Mention	2009
Enosinian Society Scholar, George Washington University	2009-2010
Distinguished Master's Thesis Award: Epidemiology Department Nominee, University of Washington	2016
National Institutes of Health TL1 Translational Health Sciences Predoctoral Trainee, University of Washington	2017-2018
National Institutes of Health T32 Substance Use, HIV, and Other Infectious Diseases Postdoctoral Trainee, The Miriam Hospital & Brown University	2021-2022
Community and Clinical Research Training Program, Brown University School of Public Health	2021-2023
Junior Faculty Implementation Science Mentoring Group, University of Washington and Fred Hutch Center for AIDS Research	2021-2023
Early Career Reviewer Program, National Institutes of Health Center for Scientific Review	2023-2025

Certifications & Licensure

Emergency Medical Technician – Basic, Washington, DC	2007-2009
Custom Power BI Developer Boot Camp, Providence, RI	2019
SAS Programming 1: Essentials, E-Learning	2019
SAS Programming 2: Data Manipulation Techniques, Boston, MA	2019

Membership in Professional Organizations

American Public Health Association	2016-2020
American Sexually Transmitted Diseases Association	2016-2019
Society for Epidemiologic Research	2017-2019
International Union against Sexually Transmitted Infections	2018-2019

Teaching Experience

Pasos Adelante (Steps Forward) Comprehensive Sexual Health Education Peer Educator Workshop Series, Peru, 12 students, Co-Instructor	2010-2012
Sexually Transmitted Infections: Causes & Consequences (EPI 220) University of Washington, 95 students, Teaching Assistant	2016

Student Mentoring

Sasha Banks. MPH Student (Epidemiology), Brown University School of Public Health. <i>Stimulant Prescribing Trends in Rhode Island</i> . Supervisor for 20 hour/week research assistantship.	2020
Sasha Banks. MPH Student (Epidemiology), Brown University School of Public Health. <i>Prescription Stimulant Use and Stimulant-Involved Fatal Overdose in Rhode Island: A Population-Based Case-Control Study</i> . Reader for MPH thesis project.	2020-2021
Taylor Fortnam. PhD Student (Biostatistics), Brown University School of Public Health. <i>Statistical Methods for Localized Monitoring with Applications to COVID-19 Surveillance</i> . Reader for doctoral dissertation.	2020-2024
Juliana Crotta-Cox. Undergraduate Student (Medical Anthropology, Human Health and Biology), Brown University. <i>Rapid Communication of Emerging Long Covid Scientific Evidence</i> . Co-supervisor for 10 hour/week research credits.	2021-2022

Amy Oh. Undergraduate Student (Biomedical Engineering), Brown University. <i>Visualization of Emerging Long Covid Scientific Evidence</i> . Co-supervisor for 10 hour/week research assistantship.	2021-2022
Abigail Murdock. MPH Student (Health Behavior), Brown University School of Public Health. <i>Mental Health Status of Rhode Island Middle School and High School Students Before Versus During the COVID-19 Pandemic</i> . Primary Advisor for MPH thesis project.	2022-2023
Hannah Reese. MPH Student (Global Health), Brown University School of Public Health. <i>Evaluation of the Association Between At-Home Environment and Mental Illness in Children and Adolescents, Stratified by Federal Poverty Level</i> . Reader for MPH thesis project.	2022-2023
Maayan Rosenfield. MPH Student (Epidemiology), Brown University School of Public Health. <i>Impact of Comorbid Chronic Pain or Mental Illness on Substance Use Treatment Among a Cohort at High Risk of Opioid Overdose</i> . Secondary Advisor for MPH thesis project.	2022-2023
Joseph Kahn. Undergraduate Student (Public Health), Brown University School of Public Health. <i>Rapid Evidence Map of Existing and Promising Disease Intervention Specialist Approaches for HIV and STIs</i> . Supervisor for 10 hour/week research assistantship.	2023
Fiona Bhondoekhan. Doctoral Student (Epidemiology), Brown University School of Public Health. <i>Characterizing Adults with a Long COVID Diagnosis in the United States</i> . Primary mentor for independent study project.	2023-2024
Senay Gokcebel. MPH Student (Epidemiology), Brown University School of Public Health. <i>Predicting the Burden of Long COVID in the United States Using the Household Pulse Survey</i> . Reader for MPH thesis project.	2023-2024
Tenzin Yangchen. PhD Student (Epidemiology), Brown University School of Public Health. <i>Trends in Recurrent Overdose Following Emergency Department Visits for Opioid Overdose, 2016-2021</i> . Primary mentor for independent study project.	2023-2024
Ralph Welwean. PhD Student (Epidemiology), Brown University School of Public Health. <i>Race-Ethnicity, Biological Sex at Birth, and Perception of Substance Use-Related Employment Stigma</i> . Primary mentor for independent study project.	2023-2025
Diahmin Hawkins. ScM Student (Biostatistics), Brown University School of Public Health. <i>Prediction of Overdose Among Emergency Department Patients at High Risk of Opioid Overdose</i> . Reader for ScM thesis project.	2024-2025
Ralph Welwean. PhD Student (Epidemiology), Brown University School of Public Health. <i>Using Administrative Health Data to Evaluate Racial and Ethnic Disparities in Addiction Treatment Engagement and Risk of Opioid Overdose</i> . Oral exam chair and committee member for doctoral dissertation.	2024-present

Community Service

Project Lead, Engineers Without Borders, Migori District, Kenya	2009
Co-Founder & Executive Director, District Youth Empowerment Program (now Serve Your City), Washington, DC	2009-2010
Undergraduate Representative, Global Initiative on the Status of Women Task Force, George Washington University	2010
Peace Corps Representative, Lucma Poverty Alleviation Committee, Peru	2010-2012
Facilitator, Lucma Pasos Adelante (Steps Forward) Technical Committee, Peru	2010-2012
Facilitator, Lucma Viviendas Saludables (Healthy Homes) Technical Committee, Peru	2010-2012
Site Development Coordinator, Nashville Mobile Market, Nashville, TN	2012
Friendship Family, Humphrey Fellowship Program, Vanderbilt University	2013-2014
Volunteer, Good Food for Good People, Nashville, TN	2013-2014
Co-Coordinator, Works in Progress Sessions, Department of Epidemiology, University of Washington	2015-2017
Co-Coordinator, Works in Progress Sessions, HIV/STD Program, Public Health – Seattle	2017-2019

& King County	
Manuscript Reviewer, <i>Clinical Infectious Diseases</i>	2018-current
Manuscript Reviewer, <i>Sexually Transmitted Diseases</i>	2018-current
Member, Data Sharing and Data Security Workgroup, Academic Institute, Rhode Island Department of Health	2019-2021
Participant, COVID-19 Expanded Public Use Dataset Workgroup, US Centers for Disease Control and Prevention	2020-2021
Participant, Department of Epidemiology Admissions Committee, Brown University School of Public Health	2021-2022
Volunteer, Harm Reduction Action Center, Denver, CO	2023
Manuscript Reviewer, <i>JAMA Health Forum</i>	2023-current
Manuscript Reviewer, <i>American Journal on Addictions</i>	2023-current
Manuscript Reviewer, <i>Drug and Alcohol Dependence</i>	2024-current
Grant Reviewer, PSI Foundation	2024
Manuscript Reviewer, <i>JAMA Network Open</i>	2025-current
Manuscript Reviewer, <i>Substance Use and Misuse</i>	2025-current
Manuscript Reviewer, <i>International Journal of Drug Policy</i>	2025-current
Volunteer, Family Tree - House of Hope Emergency Shelter, Englewood, CO	2025-current

Languages

Spanish	Certified as Advanced Medium in 2012
Quechua	Speak & comprehend at a basic level

Bibliography

(* Denotes work with a student or post-graduate trainee)

Manuscripts in Peer-Reviewed Journals

1. Wolff K, **Chambers L**, Bumol S*, White RO, Gregory BP, Davis D, Rothman RL. The PRIDE (Partnership to Improve Diabetes Education) Toolkit: Development and Evaluation of Novel Literacy and Culturally Sensitive Diabetes Education Materials. *Diabetes Educ* 2016; 42(1):23-33. PMID: 26647414, PMCID: PMC4839957.
2. **Chambers LC**, Manhart LE, Katz DA, Golden MR, Barbee LA, Dombrowski JC. Evaluation of an Automated Express Care Triage Model to Identify Clinically Relevant Cases in a Sexually Transmitted Disease Clinic. *Sex Transm Dis* 2017; 44(9):571-576. PMID: 28809775.
3. **Chambers LC**, Khosropour CM, Katz DA, Dombrowski JC, Manhart LE, Golden MR. Racial/Ethnic Disparities in the Lifetime Risk of *Chlamydia trachomatis* Diagnosis and Adverse Reproductive Health Outcomes Among Women in King County, Washington. *Clin Infect Dis* 2018; 67(4):593-599. PMID: 29420716, PMCID: PMC6070060.
4. **Chambers LC**, Manhart LE, Katz DA, Golden MR, Barbee LA, Dombrowski JC. Comparison of Algorithms to Triage Patients to Express Care in a Sexually Transmitted Disease Clinic. *Sex Transm Dis* 2018; 45(10):696-702. PMID: 29634599, PMCID: PMC6133713.
5. **Chambers LC**[†], Srinivasan S[†], Lukehart SA, Ocbamichael N, Morgan JL, Lowens MS, Fredricks DN, Golden MR, Manhart LE. Primary Syphilis in the Male Urethra – A Case Report. *Clin Infect Dis* 2019; 68(7):1231-1234. PMID: 30202933, PMCID: PMC6424071. [†]Contributed equally to this manuscript
6. **Chambers LC**, Morgan JL, Lowens MS, Robinson TS*, Romano SS*, Leipertz GL, Hughes JP, Golden MR, Khosropour CM, Fredricks DN, Manhart LE. Cross-Sectional Study of Urethral Exposures at Last Sexual Episode Associated with Non-Gonococcal Urethritis among STD Clinic Patients. *Sex Transm Infect* 2019; 95(3):212-218. PMID: 30181326, PMCID: PMC7016488.

7. **Chambers LC**, Jensen JS, Morgan JL, Lowens MS, Romano SS*, Totten PA, Soge OO, Golden MR, Manhart LE. Lack of Association Between the S83I ParC Mutation in *Mycoplasma genitalium* and Treatment Outcomes Among Men who Have Sex with Men with Nongonococcal Urethritis. *Sex Transm Dis* 2019; 46(12):805-809. PMID: 31259853, PMCID: PMC7011110.
8. **Chambers LC**, Hughes JP, Glick SN, Morgan JL, Lowens MS, Robinson TS*, Romano SS*, Leipertz GL, Khosropour CM, Fredricks DN, Golden MR, Manhart LE. Resolution of Symptoms and Resumption of Sex After Diagnosis of Nongonococcal Urethritis Among Men who Have Sex with Men. *Sex Transm Dis* 2019; 46(10):676-682. PMID: 31356530, PMCID: PMC7008972.
9. Romano SS*, Jensen JS, Lowens MS, Morgan JL, **Chambers LC**, Robinson TS*, Totten PA, Soge OO, Golden MR, Manhart LE. Long Duration of Asymptomatic *Mycoplasma genitalium* Infection After Syndromic Treatment for Nongonococcal Urethritis. *Clin Infect Dis* 2019; 69(1):113-120. PMID: 30281079, PMCID: PMC6579957.
10. Munch MM, **Chambers LC**, Manhart LE, Domogala D, Lopez A, Fredricks DN, Srinivasan S. Bacterial DNA Detection in Urine: Optimizing DNA Extraction. *PLoS One* 2020; 14(9):e0222962. PMID: 31550285, PMCID: PMC6759279.
11. Borrelli EP*, Morphis B, Youssef R, **Chambers LC**, Hallowell BD, Bratberg J, Kogut SJ. Concurrent Utilization of Prescription Opioids and Non-Opioid Controlled Substances: Rhode Island Prescription Drug Monitoring Program, 2018. *R I Med J* 2020; 103(8):53-58. PMID: 33003681, PMCID: PMC8136142.
12. Rowlinson EE*, Hughes JP, **Chambers LC**, Lowens MS, Morgan JL, Robinson TS*, Romano SS*, Leipertz GL, Soge OO, Golden MR, Manhart LE. Incidence of Non-Gonococcal Urethritis in Men who Have Sex with Women and Associated Risk Factors. *Sex Transm Dis* 2021; 48(5):341-346. PMID: 33044377, PMCID: PMC8893602.
13. Chan PA, King E, Xu Y, Goedel W, Lasher L, Vargas M, Brindamour K, Huard R, Clyne A, McDonald J, Bandy U, Yokum D, Rogers ML, **Chambers L**, Napoleon SC, Alexander-Scott N, Hogan JW. Seroprevalence of SARS-CoV-2 Antibodies in Rhode Island From a Statewide Random Sample. *Am J Public Health* 2021; 111(4):700-703. PMID: 33600249. PMCID: PMC7958024.
14. Srinivasan S, **Chambers LC**, Tapia KA, Hoffman NG, Munch MM, Morgan JL, Domogala D, Lowens MS, Proll S, Huang M, Soge OO, Jerome KR, Golden MR, Hughes JP, Fredricks DN, Manhart LE. Urethral Microbiota in Men: Association of *Haemophilus influenzae* and *Mycoplasma penetrans* with Nongonococcal Urethritis. *Clin Infect Dis* 2021; 73(7):e1684-e1693. PMID: 32750107, PMCID: PMC8492123.
15. Hallowell BD, Weidele H, Daly M, **Chambers LC**, Scagos R, Gargano L, McDonald J. History of Methadone and Buprenorphine Opioid Agonist Therapy Among People Who Died of an Accidental Opioid-Involved Overdose – Rhode Island, January 1, 2018 – June 30, 2020. *Am J Public Health* 2021; 111(9):1600-1603. PMID: 33410818, PMCID: PMC8589059.
16. Hallowell BD, **Chambers LC**, Rhodes J, Basta M, Viner-Brown S, Lasher L. Using Emergency Medical Services Data to Monitor Nonfatal Opioid Overdoses in Real Time: Development, Validation, and Use of a Case Definition, Rhode Island, 2018. *Public Health Rep* 2021; 136(1_suppl):40S-46S. PMID: 34726979, PMCID: PMC8573786.
17. Lasher L, Hallowell BD, **Chambers LC**, Koziol J, McDonald J, Elmaleh R, Karim S, Viner-Brown S. Using Timely Overdose Data to Address a Spike in Nonfatal Overdoses and Inform a Coordinated Community-Level Response in Rhode Island, 2019. *Public Health Rep* 2021; 136(1_suppl): 24S-30S. PMID: 34726976, PMCID: PMC8573778.
18. Tao J, Aristotelidis R, Zanowick-Marr A, **Chambers LC**, McDonald J, Clyne A, Mylonakis EE, Chan PA. Evaluation of the Treatment Efficacy and Safety of Remdesivir for COVID-19: a Meta-Analysis. *SN Compr Clin Med* 2021; 3(12):2443-2454. PMID: 34396045, PMCID: PMC8346348.

19. Hallowell BD, **Chambers LC**, Barre L, Diao N, Onyejekwe C, Banks A*, Bratberg J, Weidele H, Viner-Brown S, McDonald J. Association Between Initial Opioid Prescription Diagnosis Type and Subsequent Chronic Prescription Opioid Use in Rhode Island: A Population-Based Cohort Study. *BMJ Open* 2022; 12(1):e050540. PMID: 34992104, PMCID: PMC8739418.
20. Jackson TL, Chan PA, Scout NFN, Nocera LS, Crooks D, McCormick W*, Bowman S, Lasher L, Sabet Sarvestani A, **Chambers LC**. Statewide Evaluation of SARS-CoV-2 Diagnoses and Sexual Orientation and Gender Identity. *Public Health Rep* 2022; 137(3):580-587. PMID: 35238242, PMCID: PMC9109525.
21. Lewis N*, **Chambers LC**, Chu HT, Fortnam T*, De Vito R, Gargano LM, Chan PA, McDonald J, Hogan JW. Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection. *JAMA Netw Open* 2022; 5(7):e2223917. PMID: 35895058, PMCID: PMC9331088.
22. Murphy MJ, Rogers BG, **Chambers LC**, Zanolwick-Marr A, Galipeau D, Madeline N*, Scott T*, Napoleon SC, Chan PA. Characterization of Risk Factors Among Individuals with a History of Incarceration Presenting to a Sexually Transmitted Infections Clinic: Implications for HIV and STI Prevention and Care. *AIDS Patient Care STDS* 2022; 36(8):291-299. PMID: 35951448, PMCID: PMC9419926.
23. **Chambers LC**, Hallowell BD, Zang X*, Rind DM, Guzauskas GF, Hansen RN, Fuchs N, Scagos RP, Marshall BDL. The Estimated Costs and Benefits of a Hypothetical Supervised Consumption Site in Providence, Rhode Island. *Int J Drug Policy* 2022; 108:103820. PMID: 35973341, PMCID: PMC10131249.
24. McCormick W*, Karpowicz J, **Chambers LC**, Chu HT, Napoleon S, Rajotte J, Chan PA. Brief Report: Health Equity and COVID-19 Prevention in the Manufacturing Industry. *R I Med J* 2022; 105(7):62-65. PMID: 36041026.
25. Siegert TF*, **Chambers LC**, Weidele H, Scagos R, McDonald J, Onyejekwe C, Hallowell BD. Controlled Substance Prescription History Among Individuals Who Died of an Accidental Opioid-Involved Drug Overdose in Rhode Island. *Subst Use Misuse* 2022; 57(14):2142-2145. PMID: 36305842.
26. Hallowell BD, **Chambers LC**, Samuels EA, Bratberg J, McDonald J, Nitenson A, Onyejekwe C, Beaudoin FL. Sociodemographic and Prescribing Characteristics that Impact Long-Term Retention in Buprenorphine Treatment for Opioid Use Disorder Among a Statewide Population. *Drug Alcohol Depend* 2022; 241:109680. PMID: 36335834, PMCID: PMC10193454.
27. Zinsli KA*, Srinivasan S, Balkus JA, **Chambers LC**, Lowens MS, Morgan J, Rowlinson E*, Robinson TS*, Romano SS*, Munch MM, Manhart LE[†], Fredricks DN[†]. Bacterial Vaginosis Associated Bacteria in Cisgender Men Who Have Sex With Women: Prevalence, Association with Nongonococcal Urethritis, and Natural History. *Sex Transm Infect* 2023; 99(5):317-323. PMID: 36601742, PMCID: PMC10241981. [†]Contributed equally to this manuscript
28. **Chambers LC**, Morgan JL, Lowens MS, Robinson TS*, Romano SS*, Leipertz GL, Glick SN, Khosropour CM, Hughes JP, Golden MR, Fredricks DN[†], Manhart LE[†]. The Incidence Rate of Sexual Behaviors Among Cisgender Men Who Have Sex With Men Attending A Sexual Health Clinic. *Arch Sex Behav* 2023; 52(2):751-759. PMID: 35930134, PMCID: PMC9892175. [†]Contributed equally to this manuscript
29. **Chambers LC**[†], Hallowell BD[†], Samuels EA, Daly M, Baird J, Beaudoin FL. An Evaluation of the Association Between Specific Post-Overdose Care Services in Emergency Departments on Subsequent Treatment Engagement. *J Am Coll Emerg Physicians Open* 2023; 4(1):e12877. PMID: 36643599, PMCID: PMC9833281. [†]Contributed equally to this manuscript
30. **Chambers LC**[†], Hallowell BD[†], Samuels EA, Daly M, Baird J, Beaudoin FL. Evaluation of a Statewide Policy to Improve Post-Overdose Care in Emergency Departments and Subsequent

- Treatment Engagement. *RI Med J* 2023; 106(2): 34-39. PMID: 36848541, PMCID: PMC11457868. †Contributed equally to this manuscript
31. Rogers BG, Murphy M, Zanowick-Marr A, **Chambers L**, Mayard M, Galipeau D, Toma E, Almonte A, Napoleon S, Chan PA. Characterizing HIV Syndemics and the Role of Incarceration Among Men Who Have Sex with Men Presenting for Care at a Sexually Transmitted Infections Clinic. *AIDS Behav* 2023; 27(8):2513-2522. PMID: 36633764, PMCID: PMC10336172.
 32. Griffith J*, Yorlets RR*, Wentz A, Davis CS, **Chambers LC**, Beaudoin FL, Baird J, Samuels EA. Statewide Policy to Increase Provision of Take-Home Naloxone at Emergency Department Visits for Opioid Overdose. *Am J Public Health* 2023; 113(4):372-377. PMID: 36745856, PMCID: PMC10003491.
 33. Macmadu A*, Banks AJ*, Hallowell BD, Scagos RP, Hadland SE, **Chambers LC**, Marshall BDL. Receipt of Prescription Psychostimulants and Stimulant-Involved Fatal Overdose: A Population-Based Case-Control Study. *Subst Use Misuse* 2023; 58(9):1163-1167. PMID: 37170622, PMCID: PMC10247490.
 34. **Chambers LC**†, Liu T†, Hansen B†, Bazerman LB, Cachay ER, Christopoulos K, Drainoni ML, Gillani FS, Mayer KH, Moore RD, Rana A, Beckwith CG. Risk of HIV Viral Rebound in the Era of Universal Treatment in a Multi-Center Sample of Persons with HIV in Primary Care. *Open Forum Infect Dis* 2023; 10(6):ofad257. PMID: 37351454, PMCID: PMC10284343. †Contributed equally to this manuscript
 35. **Chambers LC**, Chu HT, Lewis N*, Kamat G*, Fortnam T*, Chan PA, Lasher L, Hogan JW. Effectiveness of Monoclonal Antibody Therapy for Preventing COVID-19 Hospitalization and Mortality in a Statewide Population. *RI Med J* 2023; 106(5):42-48. PMID: 37195162, PMCID: PMC11457867.
 36. **Chambers LC**†, Griffith J*†, Hallowell BD, Gaipo A, Mailloux C, Baird J, Beaudoin FL, Samuels EA. Examination of the Accuracy of Existing Overdose Surveillance Systems. *JAMA Netw Open* 2023; 6(6):e2320789. PMID: 37378980, PMCID: PMC10308251. †Contributed equally to this manuscript
 37. Bhondoekhan F*, Li Y, Gaither R*, Daly M, Hallowell BD, **Chambers LC**, Beaudoin FL, Marshall BDL. The Impact of Polysubstance Use Patterns on Engagement of Substance Use Disorder Treatment Among Emergency Department Patients at High Risk of Opioid Overdose. *Addict Behav Rep* 2023; 18:100512. PMID: 37636893, PMCID: PMC10450842.
 38. **Chambers LC**†, Hallowell BD†, Zullo AR, Paiva TJ, Berk J, Gaither R*, Hampson AJ, Beaudoin FL, Wightman RS. Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl. *JAMA Netw Open* 2023; 6(9):e2334540. PMID: 37721749, PMCID: PMC10507490. †Contributed equally to this manuscript
 39. **Chambers LC**, Park A, Cole M, Lovgren L, Zandstra T, Beaudoin FL, Collins M. Long-Term Healthcare Costs Following COVID-19: Implications for Pandemic Preparedness. *Am J Manag Care* 2023; 29(11):566-572. PMID: 37948643, PMCID: PMC11457842.
 40. Chen K, Rogers ML, Clark MA, Zandstra T, Lovgren L, Beaudoin FL, **Chambers LC**. Pandemic Preparedness and the Workforce: Employer Experiences with Long COVID. *RI Med J* 2023; 106(11):54-61. PMID: 38015788, PMCID: PMC11476069.
 41. **Chambers LC**†, Nair-Desai S†, Soto MJ, Behr C, Lovgren L, Zandstra T, Rivkees SA, Rosenthal N, Beaudoin FL, Tsai TC. Characteristics Associated With High Hospital Spending Over One Year Among Patients Hospitalized for COVID-19 in the United States: A Cohort Study. *BMJ Pub Health* 2023; 1:e000263. PMID: 40017864. PMCID: PMC11812720. †Contributed equally to this manuscript
 42. Rosenfield MN*, Beaudoin FL, Gaither R*, Hallowell BD, Daly MM, Marshall BDL, **Chambers LC**. Association Between Comorbid Chronic Pain or Prior Hospitalization for Mental Illness and

- Substance Use Treatment Among a Cohort at High Risk of Opioid Overdose. *J Subst Use Addict Treat* 2023; 159:209273. PMID: 38113996, PMCID: PMC11457827.
43. Duan K, **Chambers LC**, Basta M, Scagos RP, Roberts-Santana C, Hallowell BD. Prior Emergency Medical Services Utilization Among People Who Had an Accidental Opioid-Involved Fatal Drug Overdose – Rhode Island, 2018 –2020. *Public Health Rep* 2024; 139(1):48-53. PMID: 36891978, PMCID: PMC10905757.
 44. Murdock AR*, Rogers ML, Jackson TL, Monteiro K, **Chambers LC**. Mental Health Status of Rhode Island Middle School and High School Students Before Versus During the COVID-19 Pandemic. *J Sch Health* 2024; 94(6):489-500. PMID: 38113526, PMCID: PMC11088986.
 45. **Chambers LC**, Tapia KA, Srinivasan S, Proll S, Morgan JL, Hoffman NG, Lowens MS, Glick SN, Khosropour CM, Golden MR, Hughes JP, Manhart LE[†], Fredricks DN[†]. The Relationship Between Insertive Oral and Anal Sex and Select Measures of the Composition of the Urethral Microbiota Among Men Who Have Sex With Men. *Sex Transm Dis* 2024; 51(6):407-414. PMID: 38403292, PMCID: PMC11088528. [†]Contributed equally to this manuscript
 46. Le Brazidec DL, Cormier K, Almonte A, Napoleon S, **Chambers LC**, Tao J, Bertrand TE, Gummo CL, Beltrami J, Kinsey J, Maguire-Wilkerson A, Chan PA. Pre-Exposure Prophylaxis Care Cascade Among Men Who Have Sex With Men Engaging in Partner Notification Services at a Sexually Transmitted Infections Clinic. *AIDS Res Hum Retrovir* 2024; 40(7):435-438. PMID: 38497559, PMCID: PMC11251867.
 47. Arbaugh S*, **Chambers LC**, Gaither R*, Hallowell BD, Daly MM, Marshall BDL, Beaudoin FL. The Association Between Emergency Department Operational Metrics and Substance Use Disorder Treatment Interest in Two Rhode Island Hospitals. *RI Med J* 2024; 107(7):22-27. PMID: 38917311, PMCID: PMC11476007.
 48. **Chambers LC**, Li Y, Hallowell BD, Langdon KJ, Samuels EA, Mahoney LA, Beaudoin FL, Marshall BDL. Effect of a Peer-Led Emergency Department Behavioral Intervention on Non-Fatal Opioid Overdose: 18-Month Outcome in the Navigator Randomized Controlled Trial. *Addiction* 2024; 119(12):2116-2128. PMID: 38987890, PMCID: PMC11568958.
 49. **Chambers LC**, Malyuta Y, Goedel WC, Chan PA, Suttan Coats C, Allen K, Nunn AS. Identifying Effective Components of a Social Marketing Campaign to Improve Engagement with Express Sexual Health Services Among Gay, Bisexual, and Other Men Who Have Sex With Men: A Case Study. *JMIR Public Health Surveill* 2024; 10:e50944. PMID: 39177671, PMCID: PMC11363878.
 50. Fortnam T*, **Chambers LC**, Bilinski A, DeVita R, Gargano L, Wilson M, Hogan JW. Evaluation of Rhode Island's Early Geographic COVID-19 Vaccine Prioritization Policy. *Am J Public Health* 2024; 114(S7):S580-S589. PMID: 39197141, PMCID: PMC11424999.
 51. Yangchen T*, Rodriguez M, Baird J, Hallowell BD, Daly MM, Berk J, Gaither R*, Wightman RS, Beaudoin FL, **Chambers LC**. Trends in Recurrent Overdose and Treatment Initiation Following Emergency Department Visits for Opioid Overdose Between 2016 and 2021. *Drug Alcohol Depend* 2024; 262:111379. PMID: 38968835, PMCID: PMC11329345.
 52. Bhondoekhan F*, Li Y, Hallowell BD, Mahoney L, Daly MM, Goulet J, Beaudoin FL, **Chambers LC**, Marshall BDL. Engagement in Substance Use Disorder Treatment After an Emergency Department Visit Among Persons at High Risk of Opioid Overdose: A Prediction Analysis. *Drug Alcohol Depend Rep* 2024; 13:100287. PMID: 39498372, PMCID: PMC11534179.
 53. Armeni K, **Chambers LC**, Peachey A, Berk J, Langdon KJ, Peterson L, Beaudoin FL, Wightman RS. Randomized Clinical Trial of a 16 mg vs. 24 mg Maintenance Daily Dose of Buprenorphine to Increase Retention in Treatment Among People With an Opioid Use Disorder in Rhode Island: Study Protocol Paper. *BMJ Open* 2024; 14(11):e085888. PMID: 39521460, PMCID: PMC11551980.

54. **Chambers LC**, Welwean RA*, Cho DK*, Langdon KJ, Li Y, Hallowell BD, Daly MM, Marshall BDL, Beaudoin FL. Recovery Capital and Subsequent Overdose Risk and Addiction Treatment Engagement Among Emergency Department Patients at High Risk of Opioid Overdose. *Subst Use Misuse* 2024; 60(3):381-392. PMID: 39618048, PMCID: PMC11769765.
55. Drover CM*, Srinivasan S, Tapia KA, Munch M, Rowlinson E, **Chambers LC**, Fiedler TL, Lowens MS, Khosropour CM, Manhart LE, Fredricks DN. *Fannyhessea vaginæ* and Clearance of *Lactobacillus iners* are Associated with Incident Non-Chlamydial Non-*Mycoplasma genitalium* Urethritis in Men Who Have Sex With Women. *Sex Transm Dis* 2025; 52(5):317-324. PMID: 39718528, PMCID: PMC11991879.
56. Carrara RL*, Goedel WC, Pratty C, **Chambers LC**, Hallowell BD, Bowman S, Marshall BDL. Influence of a Pandemic on an Epidemic: A Population-Based Ecological Study of the Association Between COVID-19 Diagnoses and Drug Overdose Deaths in Rhode Island, 2023. *Public Health Rep* 2025; 140(5-6):598-604. PMID: 40852798, PMCID: PMC12378107.
57. Welwean R*, **Chambers LC**, Marshall BDL, Beaudoin FL. Risk Factors for Experiencing Substance Use-Related Employment Stigma Among Emergency Department Patients at High Risk of Opioid Overdose. *Harm Reduct J* 2025; 22(1):174. PMID: 41126196, PMCID: PMC12541974.
58. **Chambers LC**, Giguere T, Welwean RA*, Peachey AM, Wiehe SE, Aalsma MC, Ranney ML, Beaudoin FL. An Evaluation of Paid Social Media Advertising and Traditional Advertising for Addiction Research Recruitment. *Drug Alcohol Depend* 2025; 277:112923. PMID: 41109080, PMCID: PMC12671551.
59. **Chambers LC**[†], Hallowell BD[†], Zullo AR, Rodriguez M, Khan MA, Berk J, Gaither R*, Daly M, Wightman RS, Beaudoin FL. Risk of Opioid Overdose During Buprenorphine Treatment for Opioid Use Disorder in the Fentanyl Era. *Addict Behav* 2026; 175:108603. PMID: 41520431, PMCID: PMC12937454. [†]Contributed equally to this manuscript
60. Allen B, Basaraba C, Behrends CN, **Chambers LC**, Harocopos A, Marshall BDL, Cerda M. Impact of the New York City Overdose Prevention Centers on Neighborhood Commercial Activity: A Synthetic Control Analysis. *JAMA Netw Open* 2026; 9(2):e2559863. PMID: 41758519, PMCID: PMC12949448.
61. Allen B, Basaraba C, Behrends CN, **Chambers LC**, Marshall BDL, Cerda M. Neighborhood Impacts of Overdose Prevention Centers on Real Estate Prices in New York City. *Am J Epidemiol* 2026; Epub ahead of print. PMID: 41848178.
62. Fortnam TM*, **Chambers LC**, Bilinski A, King E, Huard RC, Amore E, Gargano L, McDonald J, Chan PA, Hogan JW. Dynamic Case-Control Sampling for Rapid Estimation of Vaccine Effectiveness Against an Emerging Infectious Disease Variant. *Biostatistics* 2026; 27(1):kxag002. PMID: 41972456.

Other Non-Peer-Reviewed Publications

1. **Chambers LC**, Beaudoin FL. Letter to the Editor: A Longitudinal Study of COVID-19 Sequelae and Immunity. *Ann Intern Med* 2022; 175(12):W153. PMID: 36315942.
2. Wightman RS, Beaudoin FL, **Chambers LC**. Optimizing Dosing of Medications for OUD in the Era of Fentanyl – Transforming Data Into Action is the Next Step. Medpage Today Opinion, October 22, 2023. Available at: <https://www.medpagetoday.com/opinion/second-opinions/106928>.

Conference Abstracts

1. **Chambers LC**, Khosropour CM, Katz DA, Dombrowski JC, Golden MR. Racial/Ethnic Disparities in Lifetime Risk of *Chlamydia trachomatis* (CT) Infection and Adverse Reproductive Health

- Outcomes among Women in King County, Washington. Oral presentation at the 2016 CDC STD Prevention Conference; Atlanta, GA; September 20-23, 2016. Abstract 6C1.
2. **Chambers LC**, Manhart LE, Katz DA, Golden MR, Barbee L, Dombrowski JC. Evaluation of an Express Care Triage Model for Identifying Clinically Relevant Cases in an STD clinic. Oral presentation at the 2016 CDC STD Prevention Conference; Atlanta, GA; September 20-23, 2016. Abstract 5B2.
 3. **Chambers LC**, Morgan JL, Lowens MS, Robinson T*, Romano SS*, Hughes JP, Golden MR, Manhart LE. Exposures Associated with Nongonococcal Urethritis (NGU) in Men who Have Sex with Women (MSW) and Men who Have Sex with Men (MSM). Poster presentation at the 2016 CDC STD Prevention Conference; Atlanta, GA; September 20-23, 2016. Abstract WP 56.
 4. Robinson T*, Yuhas K, **Chambers LC**, Lowens MS, Romano SS*, Morgan JL, Golden MR, Hughes JP, Fredricks DN, Manhart LE. Frequency and Sequence of Sexual Exposures in Heterosexual Men. Poster presentation at the 2016 CDC STD Prevention Conference; Atlanta, GA; September 20-23, 2016. Abstract THP 107.
 5. Romano SS*, Robinson T*, **Chambers LC**, Lowens MS, Morgan JL, Golden MR, Manhart LE. Is Exposure to Lubricant in Sexually Active Men who Have Sex with Women Only (MSW) Associated with Nongonococcal Urethritis (NGU)? Poster presentation at the 2016 CDC STD Prevention Conference; Atlanta, GA; September 20-23, 2016. Abstract THP 108.
 6. **Chambers LC**, Manhart LE, Silverman RA*, Barnabas RV. Potential Impact of Point-of-Care Testing for *Mycoplasma genitalium* Infection and Macrolide Resistance: A Mathematical Modeling Analysis. Poster presentation at the 2017 STI and HIV World Congress; Rio de Janeiro, Brazil; July 9-12, 2017. Abstract P3.130.
 7. Srinivasan S, **Chambers LC**, Hoffman NG, Morgan J, Munch MM, Yuhas K, Lowens MS, Proll S, Hughes JP, Fredricks DN, Manhart LE. The Urethral Microbiota in Nongonococcal Urethritis. Oral presentation at the 2017 STI and HIV World Congress; Rio de Janeiro, Brazil; July 9-12, 2017. Abstract O06.6.
 8. **Chambers LC**, Jensen JS, Romano SS*, Morgan JL, Lowens MS, Soge OO, Golden MR, Manhart LE (presenting author). Resistance Profiles and Treatment Outcomes among *Mycoplasma genitalium* Infected Men who Have Sex with Men with Nongonococcal Urethritis. Oral presentation at the 2018 IUSTI World and European Congress; Dublin, Ireland; June 27-30, 2018. Symposium 7.
 9. **Chambers LC**, Glick SN, Morgan JL, Lowens MS, Robinson TS*, Romano SS*, Leipertz GL, Hughes JP, Golden MR, Khosropour CM, Fredricks DN, Manhart LE. Symptom Resolution and Sex Resumption among Men who Have Sex with Men after Nongonococcal Urethritis Diagnosis. Poster presentation at the 2018 CDC STD Prevention Conference; Washington, DC; August 27-30, 2018. Abstract POS 85-T.
 10. **Chambers LC**, Hughes JP, Fredricks DN, Srinivasan S, Morgan JL, Hoffman NG, Lowens MS, Tapia KA, Glick SN, Khosropour CM, Golden MR, Manhart LE. Incidence of Sexual Behaviors and Relationship to the Urethral Microbiota Among Men who Have Sex with Men (MSM) in Seattle. Oral presentation at the 2019 STI and HIV World Congress; Vancouver, Canada; July 14-17, 2019. Abstract O07.4.
 11. Leipertz GL, **Chambers LC**, Lowens MS, Morgan JL, Romano SS*, Robinson TS*, Barbee LA, Golden MR, Manhart LE. Reassessing the Urethral Gram Stain Smear (GSS) Polymorphonuclear Leukocyte (PMN) Cutoff for Diagnosing Non-Gonococcal Urethritis (NGU). Poster presentation at the 2019 STI and HIV World Congress; Vancouver, Canada; July 14-17, 2019. Abstract P796.
 12. Rowlinson EE*, **Chambers LC**, Lowens MS, Morgan JL, Robinson TS*, Romano SS*, Leipertz GL, Golden MR, Hughes JP, Manhart LE. Risk Factors for Incident Non-Gonococcal Urethritis

- (NGU) in Men who Have Sex with Women. Poster presentation at the 2019 STI and HIV World Congress; Vancouver, Canada; July 14-17, 2019. Abstract P793.
13. Srinivasan S, **Chambers LC**, Tapia K, Hoffman NG, Munch MM, Morgan JL, Domogala D, Lowens MS, Proll S, Huang ML, Jerome KR, Golden MR, Hughes JP, Fredricks DN, Manhart LE. Urethral Microbiota in Idiopathic Nongonococcal Urethritis (NGU) in Men who Have Sex with Men and Men who Have Sex with Women. Poster presentation at the 2019 STI and HIV World Congress; Vancouver, Canada; July 14-17, 2019. Abstract P523.
 14. Bishop B*, Bratberg J, **Chambers LC**. Descriptive Analyses of Naloxone Co-Prescribing and Co-Dispensing in the Rhode Island (RI) Prescription Drug Monitoring Program (PDMP). Poster presentation at the ASHP Midyear Clinical Meeting in Las Vegas, Nevada; December 8-12, 2019. Abstract 6-416.
 15. Bishop B*, Bratberg J, **Chambers LC**. Descriptive Analyses of Naloxone Co-Prescribing and Co-Dispensing in the Rhode Island (RI) Prescription Drug Monitoring Program (PDMP). Poster presentation at the American Pharmacists Association in Washington, DC (rescheduled to virtual poster gallery); March 13-19, 2020. Abstract 465.
 16. Borrelli EP*, Morphis B, Youssef R, **Chambers LC**, Hallowell BD, Bratberg J, Kogut SJ. Concurrent Utilization of Prescription Opioids and Non-Opioid Controlled Substances: Rhode Island Prescription Drug Monitoring Program, 2018. Oral presentation at the Rural Drug Addiction Research Center's 2020 Symposium on Substance Use Research in Lincoln, Nebraska (held virtually); November 9-13, 2020.
 17. Hallowell BD, Weidele H, Daly M, **Chambers LC**, Scagos R, Gargano L, McDonald J. History of Methadone and Buprenorphine Medication-Assisted Treatment for Opioid Use Disorder Among People Who Died of an Accidental Overdose. Oral presentation at the Overdose Data to Action Grant Recipient Meeting: Addressing the Evolving Drug Overdose Epidemic (held virtually); June 22-23, 2021.
 18. Zinsli KA*, Srinivasan S, Balkus JA, **Chambers LC**, Lowens MS, Morgan J, Rowlinson E*, Robinson TS*, Romano SS*, Manhart LE, Fredricks DN. Relationship Between Three Novel Bacterial Vaginosis (BV) Associated Bacteria and Nongonococcal Urethritis in Men Who Have Sex With Women. Oral presentation at the HIV and STI World Congress; Amsterdam, Netherlands (held virtually); July 14-17, 2021. Abstract O02.4.
 19. **Chambers LC**, Hallowell BD (presenting author), Samuels EA, Daly M, Baird J, Beaudoin F. Evaluation of Statewide Treatment Standards to Improve Post-Overdose Care in Emergency Departments and Subsequent Treatment Engagement. Oral presentation at the Overdose Data to Action Grant Recipient Meeting: Resiliency and Reflections – Overcoming Challenges and Highlighting Successes (held virtually), June 14-16, 2022.
 20. Siegert TF*, **Chambers LC**, Weidele H, Scagos R, McDonald J, Onyejekwe C, Hallowell BD. Controlled Substance Prescription History Among Individuals Who Died of an Accidental Opioid-Involved Drug Overdose in Rhode Island – January 1, 2018 – December 31, 2020. Poster presentation at the Overdose Data to Action Grant Recipient Meeting: Resiliency and Reflections – Overcoming Challenges and Highlighting Successes (held virtually), June 14-16, 2022.
 21. **Chambers LC**, Rogers BG, Rose J, Zanowick-Marr A, Galipeau D, Napoleon SC, Noh M*, Scott T*, Chan PA, Murphy MJ. Characterization of Latent Subgroups Among People With a History of Incarceration Attending an STI Clinic: Implications for STI Prevention. Poster presentation at the 2022 CDC STD Prevention Conference (held virtually), September 19-20, 2022.
 22. **Chambers LC**, Nunn AS (presenting author), Malyuta Y, Suttan Coats C, Hubbard L, Chan PA. Implementation of an Express Sexually Transmitted Infection Clinic Integrated Within a Community Health Center. Oral presentation at the 2022 CDC STD Prevention Conference (held virtually), September 19-20, 2022.

23. **Chambers L**, Nunn AS, Suttan Coats C, Malyuta Y, Hubbard L, Nunez H, Napoleon S, Chan PA (presenting author). Improving Access to Pre-Exposure Prophylaxis for HIV Prevention Through Task-Shifting at a Sexually Transmitted Infections Clinic. Poster presentation at the 2022 CDC STD Prevention Conference (held virtually), September 19-20, 2022.
24. Chan PA, Malyuta Y, **Chambers L**, Suttan Coats C, Hubbard L, Reisopoulos A, Napoleon S, Salhaney P, Nunn AS. Evaluation of a Point-of-Care Sexual Transmitted Infection Test at a Community Clinic. Oral presentation at the 2022 CDC STD Prevention Conference (held virtually), September 19-20, 2022.
25. Murphy M, Rogers B, Galipeau D, **Chambers L**, Zanowick-Marr A, Napoleon SC, Noh M*, Scott T*, Sosnowy C, Chan P. Sexually Transmitted Infections (STIs) Observed Among Men Enrolled in an HIV Pre-Exposure Prophylaxis (PrEP) Implementation Program in a Correctional Setting in Rhode Island. Poster presentation at the 2022 CDC STD Prevention Conference (held virtually), September 19-20, 2022.
26. Napoleon S, Paradis-Burnett A, Almonte A, **Chambers L**, Chan PA, Pinkston MM. Screening, Brief Intervention, and Referral to Treatment for Substance Use Among Patients at a Sexually Transmitted Infections Clinic. Poster presentation at the 2022 CDC STD Prevention Conference (held virtually), September 19-20, 2022.
27. Le Brazidec D, Cormier K, Almonte A, Napoleon S, **Chambers LC**, Tao J, Bertrand TE, Howe K, Gummo CL, Ronquillo G, Chan PA. Integration of Partner Notification Services at a Sexually Transmitted Infections Clinic. Oral presentation at the 2022 CDC STD Prevention Conference (held virtually), September 19-20, 2022.
28. Le Brazidec D, Cormier K, Almonte A, Napoleon S, **Chambers LC**, Tao J, Bertrand TE, Howe K, Gummo CL, Ronquillo G, Chan PA. Pre-Exposure Prophylaxis Care Cascade Among Men Who Have Sex With Men Engaging in Partner Notification Services at a Sexually Transmitted Infection Clinic. Poster presentation at the 2022 CDC STD Prevention Conference (held virtually), September 19-20, 2022.
29. Hallowell BD, **Chambers LC**, Samuels EA, Bratberg J, McDonald J, Nitenson A, Onyejekwe C, Beaudoin FL. Do Demographic and Prescription Factors Impact Long-Term Buprenorphine Treatment Engagement? Oral presentation at the Northeast Epidemiology Conference (held virtually), November 2-4, 2022.
30. Chu H, Lewis N*, **Chambers L**, Fortnam T*, De Vito R, Gargano L, Chan P, McDonald J, Hogan J. Effectiveness of Vaccination in Preventing COVID-19 Reinfection: A Retrospective, Population-Based Cohort Study. Oral presentation at the Union World Conference on Lung Health (held virtually); November 8-11, 2022.
31. Marshall BDL, Li Y, **Chambers LC**, Samuels EA, Mahoney L, Hallowell BD, Beaudoin FL. Effect of a Peer-Led, Emergency Department-Based Behavioral Intervention on Opioid Overdose: A Randomized Controlled Trial. Oral presentation at the 11th Annual International Conference on Health and Hepatitis in Substance Users in Geneva, Switzerland; October 17-20, 2023.
32. **Chambers LC**, Hallowell BD, Zullo AR, Rodriguez M, Khan MA, Berk J, Gaither R*, Beaudoin FL, Wightman RS. Risk of Opioid Overdose While Engaged in Buprenorphine Treatment for Opioid Use Disorder in the Era of Fentanyl. Poster presentation at the Rx and Illicit Drug Summit in Atlanta, Georgia; April 1-4, 2024.
33. Bhondoekhan F*, Li Y, **Chambers LC**, Beaudoin FL, Hallowell BD, Mahoney L, Daly MM, Goulet J, Marshall BDL. Engagement in Substance Use Disorder Treatment After an Emergency Department Visit Among Persons at High Risk of Opioid Overdose: A Prediction Analysis. Oral presentation at the Society for Epidemiologic Research Conference in Austin, Texas; June 18-21, 2024.

34. Chambers LC, Welwean RA*, Mahoney LA, Wightman RS, Beaudoin FL. Methadone Treatment and Policy Considerations in the Fentanyl Era: A Single-State Case Study. Poster presentation at the Rx and Illicit Drug Summit in Nashville, Tennessee; April 21-24, 2025.
35. Allen B, Basaraba C, Behrends CN, **Chambers LC**, Harocopos A, Marshall BDL, Cerda M. Impact of the New York City Overdose Prevention Centers on Neighborhood Commercial Activity: A Synthetic Control Analysis. Oral presentation at the Society for Epidemiologic Research Annual Meeting in Boston, Massachusetts; June 10-13, 2025.
36. Welwean R*, Beaudoin FL, Marshall BDL, **Chambers LC**. Risk Factors for Experiencing Substance Use-Related Employment Stigma Among Emergency Department Patients at High Risk of Opioid Overdose. Poster presentation at the Society for Epidemiologic Research Annual Meeting in Boston, Massachusetts; June 10-13, 2025.

Select Other Oral Presentations

1. **Chambers LC**. Cytokine Induced Killer Cell Glycosylation. Oral presentation at the Molecular Imaging Program Symposium; Stanford, CA; August 22, 2007.
2. **Chambers LC**. Novel Methods to Exploit the Immune System for Early Detection and Treatment of Cancer. Oral presentation at the Molecular Imaging Program Symposium; Stanford, CA; August 18, 2008.
3. **Chambers LC**. Genomic Instability and DNA Repair: Understanding Early Carcinogenesis. Oral presentation at the Seventh Annual Symposium of the GW Undergraduate Research Award; Washington, DC; April 17, 2009.
4. **Chambers LC**, Abousmir K, Dizdar G (co-presenters). Remembering the 1961 Massacre of Algerians as a Key Element for the Recognition and Inclusion of Post-Colonial Minorities in France. Invited oral presentation at the Humanity in Action Closing Program Symposium; Paris, France; July 8, 2009.
5. **Chambers LC**. Performance-Based Financing for Maternal Health: The Impact of *Oportunidades* in Mexico. Oral defense for the review committee, Enosinian Society Scholars Program; Washington, DC; April 20, 2010.
6. **Chambers LC**. CDC STD Prevention Conference Re-Cap: Technological Innovations for STD Control. Invited oral presentation at the University of Washington STD Clinical Conference; Seattle, Washington; October 25, 2016.
7. **Chambers LC**. Sex and Symptoms in Men Who have Sex with Men: Behaviors and the Relationship with Urethral Symptoms and Inflammation. Invited oral presentation at the Annual Meeting of the NIH-funded Sexually Transmitted Infections Cooperative Research Centers; Santa Fe, NM; May 24-25, 2017.
8. **Chambers LC**. Overdose Data Sharing Pathways and Protocols. Invited oral presentation to the Public Health Academic Working Group; Providence, RI; February 24, 2020.
9. **Chambers LC**. COVID-19 Data Update with a Focus on Race and Ethnicity. Invited oral presentation to the Rhode Island Equity Council (held virtually); August 26, 2020.
10. **Chambers LC**. Employment Status of Rhode Island Residents with COVID-19. Invited oral presentation to the Office of the Rhode Island Secretary of Commerce (held virtually); October 22, 2020.
11. **Chambers LC**. Long COVID: What We Know and What We Need to Know. Invited oral presentation at the Rhode Island Department of Health Grand Rounds (held virtually); March 9, 2022.

12. **Chambers LC.** Supervised Consumption Sites. Invited oral presentation at the Substance Use and Mental Health Leadership Council Conference on Addressing HIV, HCV, and STIs in Rhode Island (held virtually); March 25, 2022.
13. **Chambers LC.** Long COVID: Epidemiology, Research, and Resources. Invited oral presentation to the Rhode Island Department of Health COVID-19 Epidemiological Operations Unit (held virtually); April 6, 2022.
14. **Chambers LC.** Application of the RIDOH Small Numbers Policy. Invited oral presentation to the Rhode Island Department of Health COVID-19 Quantitative Program (held virtually); July 21, 2022.
15. **Chambers LC, Lovgren L (co-presenters).** Long COVID. Invited oral presentation to the Rhode Island Health Equity Zones (held virtually); July 28, 2022.
16. **Chambers LC, Beaudoin FL, Lovgren L, White L (co-presenters).** Long COVID and the Workplace. Invited oral presentation to the Greater Providence Chamber of Commerce (held virtually); September 21, 2022.
17. **Chambers LC.** An Evaluation of the Association Between Specific Post-Overdose Services in Emergency Departments and Subsequent Community-Based Treatment Engagement. Invited oral presentation to the Rhode Island Department of Health Data on Overdoses for Strategic Exchange Meeting (held virtually); October 4, 2022.
18. **Chambers LC.** Overdose Prevention Centers in Rhode Island: A Cost Benefit Analysis. Invited oral presentation to the Rhode Island Governor's Overdose Prevention and Intervention Task Force (held virtually); November 9, 2022.
19. **Chambers LC.** An Evaluation of the Association Between Specific Post-Overdose Services in Emergency Departments and Subsequent Treatment Engagement. Invited oral presentation to the Rhode Island Department of Behavioral Healthcare, Developmental Disabilities, and Hospitals Behavioral Health Unit (held virtually); November 17, 2022.
20. Baird J, **Chambers LC (co-presenters).** We Can and Do Recover – Pathways Study. Invited oral presentation to the US Centers for Disease Control and Prevention Opioids Research Grantees (held virtually); January 30 - February 3, 2023.
21. **Chambers LC.** Effect of a Peer-Led, ED-Based Behavioral Intervention on Non-Fatal Opioid Overdose: An RCT. Invited oral presentation to the Rhode Island Department of Behavioral Healthcare, Developmental Disabilities, and Hospitals Behavioral Health Unit (held virtually); October 19, 2023.
22. **Chambers LC.** Identifying Optimal Buprenorphine Dosing for OUD treatment and Overdose Prevention in the Fentanyl Era. Invited oral presentation to the Yale University Veterans Aging Cohort Study Opioid Workgroup (held virtually); November 14, 2025.

Media Interviews

1. "Long COVID Initiative Investigates Long-Term COVID-19 Effects." The Brown Daily Herald, September 20, 2021. Available at: <https://www.browndailyherald.com/2021/09/20/long-covid-initiative-investigates-long-term-covid-19-effects>.
2. "Long Haul COVID and Headaches." Spotlight on Migraine Podcast, October 5, 2021. Available at: <https://spotlightonmigraine.libsyn.com/long-haul-covid-and-headaches>.
3. "COVID-19 Increases Risk of Brain Conditions for 2 Years After Infection, Study Finds." Verywell Health, August 29, 2022. Available at: <https://www.verywellhealth.com/covid-increases-brain-condition-risks-2-years-6503252>.

4. "Higher Buprenorphine Doses May Help SUD Providers Treat the 'Different Beast' That is Fentanyl." Behavioral Health Business, September 18, 2023. Available at: <https://bhbusiness.com/2023/09/18/higher-buprenorphine-doses-may-help-sud-providers-treat-the-different-beast-that-is-fentanyl/>.
5. "Buprenorphine Treatment Amid the Fentanyl Crisis: New Findings Suggest a Dose Adjustment is Needed." PsyPost, October 24, 2023. Available at: <https://www.psypost.org/2023/10/buprenorphine-treatment-amid-the-fentanyl-crisis-new-findings-suggest-a-dose-adjustment-is-needed-214130>.
6. "Brown Study Reveals Substantial Health Care Spending Following COVID-19 Infection." Brown School of Public Health News, January 24, 2024. Available at: <https://sph.brown.edu/news/2024-01-24/covid-healthcare-spending>.
7. "Trained Peers Are as Effective as Clinical Social Workers in Reducing Opioid Overdose, New Trial Finds." Addiction Press Release, July 11, 2024. Available at: <https://www.addictionjournal.org/posts/trained-peers-are-as-effective-as-clinical-social-workers-in-reducing-opioid-overdose-new-trial-finds>.
8. "New Study Looks at Peer Support in the Emergency Room for Addiction." Theravive, July 30, 2024. Available at: <https://www.theravive.com/today/post/new-study-looks-at-peer-support-in-the-emergency-room-for-addiction-0005007.aspx>.

Research Funding

Ongoing Support

- R01 DA062186, NIH/NIDA (Francesca Beaudoin / Andrew Zullo / Rachel Wightman)
Optimizing Methadone Treatment Strategies for Opioid Use Disorder in the Era of Fentanyl
Project period: 9/1/2025-5/31/2030
Role: Lead Research Scientist
- R01 DA058277, NIH/NIDA (Magdalena Cerda / Brandon Marshall)
A Comparative Evaluation of Overdose Prevention Programs in New York City and Rhode Island
Project period: 5/1/2023-2/28/2027
Role: Co-Investigator
- UG3/UH3 DA056880, NIH/NIDA (Francesca Beaudoin / Rachel Wightman)
Identifying Optimal Buprenorphine Dosing for OUD Treatment and Prevention of Overdose
Project period: 7/1/2022-11/30/2027
Role: Lead Research Scientist
- R01 DA054698, NIH/NIDA (Francesca Beaudoin / Megan Ranney)
Increasing Peer Support for OUD Recovery During COVID-19 Through Digital Health: A National Randomized Controlled Trial
Project period: 8/15/2021-7/31/2026
Role: Lead Research Scientist
- P20 GM125507, NIH/NIGMS (Josiah Rich / Brandon Marshall)
COBRE on Opioids and Overdose Core B: Data and Research Methods
Project period: 9/1/2018-8/31/2028
Role: Data and Research Methods Core Manager

Previous Support

Annenberg Community Engaged Education Research Fund (Laura Chambers / Joseph Hogan / Alyssa Bilinski)

Using Illness-Related School Absenteeism Data to Inform Timely Response to Respiratory Infections

Project period: 7/1/2024-8/31/2025

Role: Co-Principal Investigator

Contract, Rhode Island Department of Health (Brandon Marshall / Alexandra Collins)

Rhode Island Community Disease Intervention Specialist Assessment Project

Project period: 2/1/2023-4/30/2024

Role: Lead Research Scientist

R25 MH083620, NIH/NIMH (Amy Nunn / Leandro Mena)

The Brown Initiative in HIV/AIDS Clinical Research for Minority Communities

Project period: 4/1/2021-1/31/2026

Role: Research Fellow

Hassenfeld Family Foundation (Francesca Beaudoin)

Development of an Initiative to Rapidly Study and Communicate the Impact of Long COVID

Project period: 7/1/2021-12/31/2022

Role: Co-Director, Lead of Survey Research, Lead Research Scientist

Contract, Rhode Island Department of Health (Joseph Hogan)

Analytics support for the COVID-19 Response in Rhode Island

Project period: 5/19/2020-6/30/2025

Role: Contract Epidemiologist

R01 CE19001, CDC (Francesca Beaudoin / Janette Baird)

Implementing Statewide Emergency Department Care Pathways for Addiction Recovery After Opioid Overdose

Project period: 9/30/2019-9/29/2024

Role: Consultant Epidemiologist, Lead Research Scientist

NU17CE924967, CDC (Jennifer Koziol / Leanne Lasher)

Overdose Data to Action

Project period: 9/1/2019-8/31/2022

Role: Lead of Overdose Risk and Protective Factors Epidemiology Team / Inter-Agency Projects

Laura and John Arnold Foundation (Brandon Marshall / Francesca Beaudoin)

ED-based Behavioral Interventions Following Opioid Overdose: The Impact of Peer Navigation on Treatment Engagement, Relapse, and Recovery (The Navigator Trial)

Project period: 8/31/2018-7/31/2024

Role: Lead Research Scientist

T32 DA013911, NIH/NIDA (Timothy Flanigan / Josiah Rich)

HIV and Other Infectious Consequences of Substance Abuse, T32 Postdoctoral Training Program

Project period: 7/1/2017-6/30/2022

Role: Postdoctoral Trainee

U19 AI113173, NIH/NIAID (Anna Wald)

University of Washington Sexually Transmitted Infections Cooperative Research Center: The Genital Microbiome as a Determinant of Sexual Health and Local Immunity; Project 3 – Urethral Microbiome and Non-Gonococcal Urethritis in Men Who Have Sex with Men

Project period: 7/1/2014-12/31/2020
Role: Study Manager, Research Scientist

TL1 TR002318, NIH/NCATS (Linda LeResche / Joie Whitney)
Institute for Translational Health Sciences, TL1 Translational Research Training Program
Project period: 6/1/2013-2/28/2018
Role: Predoctoral Trainee

5R18 DK083264, NIH/NIDDK (Russell Rothman)
Public-Private Partnership Addressing Literacy-Numeracy to Improve Diabetes Care
Project period: 7/15/2010-6/30/2015
Role: Bilingual Research Analyst II